Tianjin COSYCHEM Technology

Established in October 2010, Tianjin COSYCHEM Technology Co., Ltd. operates as a pivotal supplier of chemical raw materials for the life sciences sector. The company, founded by Song Yanmin, has strategically positioned itself within China's biopharmaceutical landscape. After more than a decade of technological development, COSYCHEM has built a comprehensive business model that encompasses specialized pharmaceutical intermediates, raw materials for diagnostic analytics, and components for nucleic acid drugs.

The firm functions as a Contract Development and Manufacturing Organization (CDMO), providing integrated services from research and development to production for life science enterprises. Its operations are centered around multiple technology platforms, including synthetic technology, gene therapy delivery, nucleic acid drug discovery, and in-vitro diagnostics (IVD) services. The company's revenue is generated through the sale of its products and its CRO and CDMO services. COSYCHEM serves a client base primarily composed of pharmaceutical and life science companies.

COSYCHEM's product portfolio is extensive, featuring core materials for both in-vitro diagnostics and nucleic acid therapeutics. Key offerings include a delivery system for small nucleic acid drugs, known as GALNAc, and the capability to produce phosphoramidite monomers in multi-kilogram quantities. The company has also developed a cationic lipid library to create LNP delivery systems for gene therapy applications. To bolster its research capabilities, the company has forged strategic partnerships, establishing a joint laboratory for nucleic acid drug innovation with Peking University Health Science Center and a genomic nucleic acid technology platform with Nankai University. These collaborations are intended to advance the downstream application of nucleic acid drugs and vaccines.

Financially, the company has demonstrated significant growth, securing over RMB 200 million in financing over three years and completing a Pre-B round exceeding CNY 100 million in May 2024. This capital is earmarked for the commercial expansion of its biological technology chemical raw materials and their applications in nucleic acid drugs and IVD. COSYCHEM holds over 50 independent intellectual property rights and has received numerous national-level recognitions, including being named a National High-tech Enterprise and a National Recognized "Little Giant" Enterprise.

Keywords: nucleic acid drug raw materials, CDMO services, life sciences, gene therapy, in-vitro diagnostics, phosphoramidite monomer, GALNAc delivery system, LNP delivery systems, custom synthesis, biopharmaceutical, pharmaceutical intermediates, molecular diagnosis raw materials, CRO services, gene synthesis, Tianjin Quanhecheng, Song Yanmin, genetic testing, drug discovery, chemical raw materials, life science partner